Home/Pipeline/PCI for Nucleic Acid Delivery

PCI for Nucleic Acid Delivery

Dermatology

PreclinicalTerminated (Liquidation)

Key Facts

Indication

Dermatology

Phase

Preclinical

Status

Terminated (Liquidation)

Company

PCI Biotech

About PCI Biotech

PCI Biotech leveraged its photochemical technology platform, originating from research at Oslo University Hospital, to address key challenges in drug delivery and biomanufacturing. The company focused on two main applications: PCI for enhancing the intracellular delivery of therapeutics in oncology and dermatology, and PCL for improving yield and purity in viral vector manufacturing for gene therapies. Despite reaching preclinical and early clinical stages with its technologies, the company's shareholders resolved to dissolve and delist the company in 2026, ceasing its development activities.

View full company profile

Therapeutic Areas

Oncology Dermatology Bioprocessing

Other Dermatology Drugs

Drug	Company	Phase	Status
Not specified in provided content	3Sbio	Various	Active
Tretinoin Gel	Avecho Biotechnology	Preclinical	Active
Dermatology Candidates	Aucta Pharmaceuticals	Not Specified	Active R&D
Undisclosed Transcription Factor Program	Montai Therapeutics	Development Candidate (DC) expected 2026	Active
Undisclosed Biologic Replacement Program	Montai Therapeutics	Development Candidate (DC) expected 2027	Active